Would You Edit a Childs DNA Before Birth to Prevent Disease?
- Alexia Abramova
- Jul 23
- 7 min read
In 2018, one announcement made the future feel suddenly close and deeply unsettling. A scientist in China, He Jiankui, said he had used CRISPR to alter the DNA of twin girls before birth. His stated goal was to make them resistant to HIV by changing a gene called `CCR5`.
Many scientists reacted with alarm. Not because preventing disease is a bad goal, but because the experiment crossed a line before the world had agreed where that line should be. The risks were unknown. The children could not consent. Any changes could affect not only them, but possibly their future descendants.
He was later sentenced to prison.
That case still hangs over one of the hardest questions in science and medicine: if we could prevent a child from being born with a devastating genetic disease, should we edit their DNA before birth?
This article is informational only and does not offer medical advice.
What CRISPR can do and why it feels so powerful
CRISPR is often described as a pair of molecular scissors. That image is useful, but it is too simple.
In practice, CRISPR is a tool scientists can program to find a specific stretch of DNA. Once it reaches that location, it can cut the DNA. The cell then repairs the break. Scientists can use that repair process to disable a gene, correct a mutation, or change how a gene works.
That is a major achievement. Many genetic diseases are caused by changes in DNA. Some are linked to one gene. Others involve many genes, environment, chance, and timing.
The appeal is easy to understand. If a child faces a high risk of a severe genetic disorder, editing the disease-causing mutation before birth sounds like mercy. It sounds cleaner than treating symptoms later. It sounds like preventing suffering before it starts.
But DNA is not a simple typo in a document. Genes interact. One change can have many effects. A gene that raises risk in one setting may offer protection in another. The same `CCR5` gene involved in the 2018 case is tied to HIV resistance, but changing it may also affect immune function in ways scientists do not fully understand.
That uncertainty sits at the heart of the debate.
There are two very different kinds of gene editing
The ethics change a lot depending on what kind of editing we mean.
Somatic editing changes one patient
Somatic gene editing targets cells in a person who already exists. For example, a therapy might edit blood cells, immune cells, or cells in a specific tissue. The change affects that patient, not their children.
This kind of editing still carries risk, but it fits more easily into familiar medical ethics. A patient can usually consent. A doctor can weigh benefits and harms. Regulators can review the treatment. If something goes wrong, the effects may be limited to that person.
Somatic gene therapies are already being studied and used in some serious diseases, especially when the disease is life-threatening and other options are poor.
Germline editing changes future generations
Editing an embryo, sperm, or egg is different. This is called germline editing. If an edited embryo becomes a child, changes may exist in every cell of that child’s body. They may also be passed to future children.
That makes germline editing much harder to justify.
The person most affected cannot agree to the procedure. Future generations cannot agree either. If the edit causes harm later in life, the decision cannot be undone. The stakes are not just medical. They are social, legal, moral, and personal.
This is why many scientists draw a hard line between treating a living patient and editing an embryo before birth.
The strongest argument for editing before birth
The most powerful case for embryo editing is compassion.
Some genetic diseases are severe, painful, and fatal at a young age. Families who carry these conditions may face heartbreaking decisions. If a safe gene edit could prevent a child from developing such a disease, many people would see that as a responsible act.
Parents already make medical choices for future children in other ways. They may use carrier screening. They may choose in vitro fertilization with genetic testing. They may avoid passing on a known disorder when possible. Seen from that angle, DNA editing could look like one more tool for protecting a child.
The strongest version of the argument has strict limits. It is not about choosing eye color, height, athletic ability, or intelligence. It is about preventing a serious disease when no safer option exists.
That matters. Most people who support medical gene editing do not support a free-for-all. They imagine rare cases with clear medical need, strong evidence, careful oversight, and no realistic alternative.
A future case might look like this:
Both parents carry a mutation that gives any child a near-certain chance of a devastating disease.
Embryo screening cannot produce an unaffected embryo.
The disease has no good treatment.
The gene involved is well understood.
The edit has been tested for safety over many years.
Independent review boards, doctors, scientists, ethicists, and regulators agree the benefit is strong enough to justify the risk.
That is a narrow door. But some argue it should not be locked forever.
The strongest argument against it
The case against editing a child’s DNA before birth begins with humility.
Science has a long history of reaching beyond what it understands. CRISPR is precise compared with older methods, but it is not magic. Edits can happen in unintended places. Cells in the same embryo may not all be edited in the same way. A change that looks safe at birth may cause problems decades later.
Then there is the consent problem. Parents can consent to many medical treatments for children, but germline editing is different because the changed person will live with the result forever. Their descendants may live with it too.
A decision made in a lab could become a biological inheritance.
There is also a fairness problem. If embryo editing becomes available, who gets access? Wealthy families first? Countries with looser rules? Clinics willing to sell hope before safety is proven?
Medical need can also slide into preference. Once society accepts editing embryos to prevent severe disease, the pressure may grow to edit for traits that are not diseases at all. The line between health and enhancement is not always clean.
For example, is editing to prevent early-onset fatal disease acceptable? Many would say yes, if safe. What about editing to reduce adult cancer risk? What about lowering risk for depression, diabetes, or Alzheimer’s disease when risk depends on many genes and life factors? What about making a child taller because short stature is socially stigmatized?
At some point, medicine becomes selection. At another point, selection becomes design.
The 2018 CRISPR babies case showed what can go wrong
The 2018 case shocked the scientific world because it appeared to move from possibility to practice before broad agreement, public trust, and safety standards were in place.
He Jiankui said he edited embryos to alter the `CCR5` gene. The goal was to reduce the children’s risk of HIV infection. Critics pointed out several problems.
HIV can usually be prevented through safer methods. The edit was not needed to save the children from an unavoidable genetic disease. The long-term risks were unclear. The consent process was widely criticized. The work did not reflect a global scientific consensus.
The reaction was swift because the case seemed to violate a basic principle: do not expose children to unknown lifelong risks for a benefit that can be achieved in safer ways.
That principle still matters.
A future use of embryo editing would need a much stronger reason than changing HIV risk. It would need to address a severe genetic condition that cannot be avoided or treated by safer means.
The question is not just whether we can
The public debate often frames gene editing as fear versus progress. That framing misses the real issue.
The question is not whether science should stop. Science should keep studying genetics. Researchers should keep developing treatments. Families facing genetic disease deserve better options, not lectures from people untouched by those choices.
The real question is whether society can build rules strong enough to separate healing from experimentation.
Those rules would need to include:
Clear medical limits
Long-term safety evidence
Public oversight
Independent ethics review
Transparency about failures as well as successes
Equal concern for children, families, and future generations
Global cooperation so risky work does not simply move to less regulated places
Regulation cannot remove every risk. But a lack of regulation almost guarantees abuse.
Where I would draw the line
If the question is whether I would edit a child’s DNA before birth today, my answer is no.
Not because preventing disease is wrong. It is because heritable embryo editing is not yet safe, accountable, or socially settled enough for real children to bear the burden of our confidence.
If the question is whether I would rule it out forever, my answer is also no.
There may be a future where germline editing becomes safe enough, narrow enough, and necessary enough to prevent a terrible disease. In that future, saying no in every case could also cause harm. Ethics is not only about preventing reckless action. It is also about not ignoring suffering when a responsible solution exists.
So the better answer is conditional.
I would consider it only when all of these are true:
The disease is severe and strongly genetic.
No safer option can prevent it.
The edit has strong evidence of safety and accuracy.
The goal is treatment, not enhancement.
Independent oversight is strict and public.
Long-term follow-up is required.
Society has had a real say, not just scientists and private clinics.
That is a high bar. It should be.
A child is not just a medical outcome
The hardest part of this debate is that both sides care about children.
One side sees a chance to spare a child from pain. The other sees a child exposed to risks no one fully understands. Both concerns are real.
That is why the answer cannot be simple excitement or simple fear. CRISPR may become one of the most important medical tools ever developed. It may help treat diseases that once seemed untreatable. But editing embryos before birth asks for more than scientific skill. It asks for moral patience.
A child’s genome is not a product to improve. It is part of a person who will grow, choose, suffer, love, and live with decisions made before they had a voice.
If we ever edit DNA before birth to prevent disease, it should happen only after society proves it can protect the child more fiercely than it protects the promise of the technology.
Comments